KCT0007299进行中（未招募）未知
A randomized, open-label, and single-dose exploratory clinical study to compare the pharmacokinetic characteristics and the safety between after administration of UI064 and co-administration of UIC202007 and UIC202008 in healthy adult subjects
Korea United Pharm0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 55(Year)（—）
- 性别
- All
入选标准
- •1) A healthy adult between 19 and 55 years of age at the time of screening test
- •2) A person who weighs more than 50 kg and whose calculated BMI is within the range of 18.0-29.0 kg/m2.
- •? BMI = (weight [kg])/(height [m])2
- •3) A person who is judged to be eligible for the test through physical examination and history taking according to this test plan. That is a person who has no congenital or chronic disease and has no pathological symptoms or findings as a result of internal examination within the past three years.
- •4) A person who is judged to be suitable for clinical laboratory examination and ECG results conducted according to this test plan (if the tester determines that the clinical laboratory examination and ECG results are not clinically meaningful even if they are within or beyond the reference value of Inha University Medical School)
- •5) A person who has heard and fully understood this clinical trial, agreed to comply with the precautions, and has decided to participate voluntarily in written consent.
排除标准
- •1) A person who has or has a history of clinically significant cardiovascular, respiratory system, liver, kidney, nervous system, endocrine system, blood/tumor, mental illness, or urinary system
- •2) A person who has or has a history of gastrointestinal diseases which may affect the absorption of medications for clinical trials (gastrointestinal ulcer, gastritis, stomach cramps, gastrointestinal reflux disease, Crohn's disease, etc.) or who has a history of gastrointestinal surgery (except simple appendectomy or hernia surgery)
- •3) A person who has genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- •4) A person who has a history of hypersensitivity or clinically significant hypersensitivity to montelukast, bepotastine, drugs containing the same family of montelukast or bepotastine, or other medications (aspirins, antibiotics, etc.)
- •5) A person who showed a clinically significant low blood pressure (systolic blood pressure < 90mmHg) or high blood pressure (systolic blood pressure = 150mmHg or diastolic blood pressure = 95mmHg) during the screening test
- •6) A person whose screening tests show any of the following results:
- •- AST or ALT > Double the upper limit of the normal range
- •- Total bilirubin > 2.0 mg/dL
- •- Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2
- •7) A person who continuously drinks alcohol (more than 21 units/week, 1 unit = 10 g = 12.5 mL of pure alcohol) or is unable to stop drinking alcohol during clinical trials
- •8) A person who continuously smokes (more than 10 cigarettes/day) or is unable to quit smoking during the period of admission of this clinical trial
- •9) A person who participated in other clinical trials or biological equivalence tests within six months (the last day of taking medication for clinical or biological equivalence tests) prior to the date of first administration
- •10) A person who has donated whole blood within 60 days before the first injection date, or who has donated blood within 30 days, or who has received blood transfusion within 30 days
- •11) A person who has taken any prescription medication or herbal medicine within 14 days prior to the first day of administration or who has taken any general medication (OTC) within 7 days (However, they may participate in clinical trials if other conditions are reasonable according to the tester's judgment)
- •12) A person who has taken medication that can induce or inhibit drug metabolism such as barbital drugs, within one month prior to the date of first administration
- •13) A person who has had a diet (especially grapefruit juice or its products) within seven days prior to the date of first administration that may affect the absorption, distribution, metabolism, or excretion of the drugs
- •14) A person who has not agreed to exclude the possibility of pregnancy by using medically recognized contraception* from the first day of administration to the 7th day after the last day of administration.
- •* Medically recognized contraception: Using combination of intrauterine devices, vasectomy, tubal ligation, and barrier contraception method (condoms for male, condoms for female, pessary, contraceptive diaphragm, sponges, etc.) or using more than two kinds of barrier contraception method when using a salivary agent
- •15) A pregnant or childbearing potential woman and breast-feeding woman
- •16) A person with mental illness and drug addiction
- •17) A person who is not willing or unable to comply with th
研究者
相似试验
招募中
不适用
A randomized, open-label, and single-dose study to evaluate the safety and the pharmacokinetics after concurrent administration of UIC202007 and UIC202008 in healthy adult subjectsKCT0005901Korea United Pharm30
已完成
1 期
Mass balance study of [14C]-REN001 in healthy male subjectsPrimary mitochondrial myopathy (rare genetic diseases that cause muscles to not function properly)Genetic DiseasesISRCTN57533271Reneo Pharma Ltd6
进行中（未招募）
1 期
FG001 in patients with non-small cell lung canceron-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-004389-37-DKFluoGuide A/S44
已完成
1 期
Comparative assessment of the absorption of a generic formulation of atorvastatin oral spray against the innovator atorvastatin capsule conducted under fasting conditions in healthy male and female volunteersPilot pharmacokinetic study conducted in healthy volunteers comparing two formulations of atorvastatin (oral spray and capsule) with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, atorvastatin is used as an adjunct to diet for the treatment of patients with hypercholesterolaemia.Pilot pharmacokinetic study conducted in healthy volunteers comparing two formulations of atorvastatin (oral spray and capsule) with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, atorvastatin is used as an adjunct to diet for the treatment of patients with hypercholesterolaemia.Blood - Other blood disordersMetabolic and Endocrine - Other metabolic disordersACTRN12618000208202Zenith Technology Corp Ltd12
已完成
1 期
A randomised, open label study to compare the bioavailability of 12mg (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid capsules against the innovator 10mg (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid capsules conducted under fasting condition in healthy male volunteers.Tretinoin capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(1517) translocation and/or the presence of the PML/RARa gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated. Tretinoin is for the induction of remission only.Cancer - Leukaemia - Chronic leukaemiaACTRN12620000287932Zenith Technology Corporation Limited24